| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Bilobalide (BB) is a naturally occuring and biologically active terpenic trilactone isolated from Ginkgo biloba (GB). In vitro experiments showed that inhibition by BB and GB was eliminated in mutant receptors containing T6'S and S12'A substitutions, but their potencies were increased (42 and 125-fold, respectively) in S2'A mutant receptors, demonstrating the neuroprotective effects of this compound. By decreasing the β amyloid protein (A), a Aβ by-product of amyloidogenic processing of APP, and increasing the secretion of -secretase-cleaved soluble amyloid precursor protein (sAPPα), BB improved non-amyloidogenic processing of APP.
| Targets |
Human Endogenous Metabolite
|
||
|---|---|---|---|
| ln Vitro |
Bilobalide (1-100 µM) completely suppresses the NMDA-evoked release of choline in a concentration-dependent manner with IC50 value of 2.3 µM[1].
Bilobalide (1, 5 and 10 μM) alone for 24 h does not affect cell viability of SH-SY5Y cells. The best protective effect was obtained at 10 μM[2], and pre-treating cells with bilobalide prevents Aβ 1-42, H2O2, and serum deprivation-induced decreases in cell viability. Bilobalide (5 and 10 μM; 24 h) treatment dose-dependently raises levels of p-Akt (Ser473 and Thr308) in SH-SY5Y cells[2]. |
||
| ln Vivo |
Bilobalide (20 mg/kg) completely suppresses the NMDA-induced release of choline in vivo while basal choline levels were not significantly affected. When NMDA is retrograde dialyzed into the hippocampus of freely moving rats, this results in the release of choline in vivo. The effect caused by NMDA is completely inhibited by bilobalide (20 mg/kg intravenously)[1].
|
||
| Animal Protocol |
|
||
| References |
|
||
| Additional Infomation |
Bilobalide is a terpenoid trilactone found in extracts of Ginkgo biloba.
Bilobalide has been reported in Ginkgo biloba with data available. See also: Ginkgo (part of). |
| Molecular Formula |
C15H18O8
|
|
|---|---|---|
| Molecular Weight |
326.3
|
|
| Exact Mass |
326.1
|
|
| Elemental Analysis |
C, 55.21; H, 5.56; O, 39.23
|
|
| CAS # |
33570-04-6
|
|
| Related CAS # |
|
|
| PubChem CID |
73581
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.6±0.1 g/cm3
|
|
| Boiling Point |
651.7±55.0 °C at 760 mmHg
|
|
| Flash Point |
247.5±25.0 °C
|
|
| Vapour Pressure |
0.0±4.4 mmHg at 25°C
|
|
| Index of Refraction |
1.606
|
|
| LogP |
-0.45
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
8
|
|
| Rotatable Bond Count |
1
|
|
| Heavy Atom Count |
23
|
|
| Complexity |
650
|
|
| Defined Atom Stereocenter Count |
6
|
|
| SMILES |
O=C(O1)C[C@@]2([C@]1([H])C[C@]3(C(C)(C)C)O)[C@@]34[C@](OC([C@@H]4O)=O)([H])OC2=O
|
|
| InChi Key |
MOLPUWBMSBJXER-YDGSQGCISA-N
|
|
| InChi Code |
InChI=1S/C15H18O8/c1-12(2,3)14(20)4-6-13(5-7(16)21-6)10(19)23-11-15(13,14)8(17)9(18)22-11/h6,8,11,17,20H,4-5H2,1-3H3/t6-,8-,11-,13-,14+,15+/m0/s1
|
|
| Chemical Name |
(1S,4R,7R,8S,9R,11S)-9-tert-butyl-7,9-dihydroxy-3,5,12-trioxatetracyclo[6.6.0.01,11.04,8]tetradecane-2,6,13-trione
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.37 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0647 mL | 15.3233 mL | 30.6466 mL | |
| 5 mM | 0.6129 mL | 3.0647 mL | 6.1293 mL | |
| 10 mM | 0.3065 mL | 1.5323 mL | 3.0647 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02425436 | Completed | Drug: Ginkgo Biloba Extract Other: Placebo |
Intrauterine Growth Restriction (IUGR) |
Assiut University | May 2014 | Phase 2 |
| NCT03475823 | Completed | Dietary Supplement: Ginkgo biloba Dietary Supplement: Placebo control |
Affect Neuroimaging |
Northumbria University | February 17, 2017 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA